patients clinical-trials-their-design-location-and-potentially-their-simulation 
PharmaShots
APRIL 3, 2023
Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory gout Starting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. Shots: The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals.
Pharmaceutical Technology
AUGUST 3, 2022
The discovery of a new chemical entity (NCE) that could potentially lead the way to a ground-breaking therapeutic treatment is an exciting prospect for any chemist. The potential to use these scientific breakthroughs to make a real difference to patients’ lives is what drives many highly skilled scientists to the world of drug development.
Expert insights. Personalized for you.
40 
Let's personalize your content